China Blocks Pharma’s Herbal Injection After Three Deaths
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities moved to block an herbal injection made by a pharmaceutical firm after three patients died of strong adverse reactions to the Siberian ginseng treatment made by Wandashan Pharmaceuticals. The State FDA ordered use and distribution of the injection suspended after the adverse reactions reported in a single province of the nation. The herbal injections are used to treat thrombosis resulting from weak livers or kidneys, and for curing heart problems. (Click here for more
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.